Olpasiran

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

Peter Attia MD

An siRNA compound developed by Amgen targeting Lp(a), with data released in Nature Medicine.